197 related articles for article (PubMed ID: 36823443)
1. RAGA prevents tumor immune evasion of LUAD by promoting CD47 lysosome degradation.
Zhang L; Yu J; Zheng M; Zhen H; Xie Q; Zhang C; Zhou Z; Jin G
Commun Biol; 2023 Feb; 6(1):211. PubMed ID: 36823443
[TBL] [Abstract][Full Text] [Related]
2. EGFR-Induced and c-Src-Mediated CD47 Phosphorylation Inhibits TRIM21-Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion.
Du L; Su Z; Wang S; Meng Y; Xiao F; Xu D; Li X; Qian X; Lee SB; Lee JH; Lu Z; Lyu J
Adv Sci (Weinh); 2023 Sep; 10(27):e2206380. PubMed ID: 37541303
[TBL] [Abstract][Full Text] [Related]
3. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
[TBL] [Abstract][Full Text] [Related]
4. α5-nAChR/STAT3/CD47 axis contributed to nicotine-related lung adenocarcinoma progression and immune escape.
Kang G; Jiao Y; Pan P; Fan H; Li Q; Li X; Li J; Wang Y; Jia Y; Wang J; Sun H; Ma X
Carcinogenesis; 2023 Dec; 44(10-11):773-784. PubMed ID: 37681453
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
6. Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47.
Hu H; Cheng R; Wang Y; Wang X; Wu J; Kong Y; Zhan S; Zhou Z; Zhu H; Yu R; Liang G; Wang Q; Zhu X; Zhang CY; Yin R; Yan C; Chen X
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36413402
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC.
Nigro A; Ricciardi L; Salvato I; Sabbatino F; Vitale M; Crescenzi MA; Montico B; Triggiani M; Pepe S; Stellato C; Casolaro V; Dal Col J
Front Immunol; 2019; 10():3135. PubMed ID: 32082304
[TBL] [Abstract][Full Text] [Related]
8. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
[TBL] [Abstract][Full Text] [Related]
9. Exosomal CD47 Plays an Essential Role in Immune Evasion in Ovarian Cancer.
Shimizu A; Sawada K; Kobayashi M; Yamamoto M; Yagi T; Kinose Y; Kodama M; Hashimoto K; Kimura T
Mol Cancer Res; 2021 Sep; 19(9):1583-1595. PubMed ID: 34016744
[TBL] [Abstract][Full Text] [Related]
10. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
11. Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer.
Arrieta O; Aviles-Salas A; Orozco-Morales M; Hernández-Pedro N; Cardona AF; Cabrera-Miranda L; Barrios-Bernal P; Soca-Chafre G; Cruz-Rico G; Peña-Torres ML; Moncada-Claudio G; Ramirez-Tirado LA
Cancer Med; 2020 Apr; 9(7):2390-2402. PubMed ID: 32043750
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
[TBL] [Abstract][Full Text] [Related]
13. Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis.
Li J; Yan S; Li Q; Huang Y; Ji M; Jiao X; Yuan M; Wang G
Mol Hum Reprod; 2022 Apr; 28(5):. PubMed ID: 35404426
[TBL] [Abstract][Full Text] [Related]
14. The ubiquitination of rag A GTPase by RNF152 negatively regulates mTORC1 activation.
Deng L; Jiang C; Chen L; Jin J; Wei J; Zhao L; Chen M; Pan W; Xu Y; Chu H; Wang X; Ge X; Li D; Liao L; Liu M; Li L; Wang P
Mol Cell; 2015 Jun; 58(5):804-18. PubMed ID: 25936802
[TBL] [Abstract][Full Text] [Related]
15. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
16. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
[TBL] [Abstract][Full Text] [Related]
17. Restoration of miR-340 controls pancreatic cancer cell
Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
[TBL] [Abstract][Full Text] [Related]
18. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
[TBL] [Abstract][Full Text] [Related]
19. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Tong B; Wang M
Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
[TBL] [Abstract][Full Text] [Related]
20. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
Peluso MO; Adam A; Armet CM; Zhang L; O'Connor RW; Lee BH; Lake AC; Normant E; Chappel SC; Hill JA; Palombella VJ; Holland PM; Paterson AM
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]